Clinical bottom line
Emerging evidence supports a significant role of the gut microbiome in modulating anxiety and depression via the microbiota-gut-brain axis. Alterations in gut microbial composition and function appear linked to neuroinflammation, stress responses, and neurotransmitter regulation relevant to mood disorders. While preclinical and early clinical studies suggest that targeting the gut microbiome through diet, probiotics, or nutraceuticals may offer adjunctive benefits, robust clinical trials are needed to establish efficacy and guide integration into psychiatric practice (Parmar et al., 2023; Moloney et al., 2016).
What the evidence shows
Parmar et al. (2023) review the interplay between inflammation, gut microbiota, and mood disorders, highlighting that dysbiosis can promote systemic and neuroinflammation implicated in anxiety and depression pathophysiology. They discuss mechanisms including altered short-chain fatty acid production and immune activation.
Moloney et al. (2016) focus on stress-induced changes in the microbiota-gut-brain axis, demonstrating how stress alters gut permeability and microbial diversity, which in turn modulates visceral pain and emotional behavior relevant to irritable bowel syndrome and comorbid anxiety.
Zavala-Medina et al. (2026) extend these findings to neuroinflammatory processes, linking oral and gut dysbiosis to neurodegenerative and mood disorders through systemic inflammatory pathways.
Padgett et al. (2023) emphasize the bidirectional relationship between diet, stress, depression, and gut microbiota composition, suggesting that dietary interventions may modulate microbial profiles to improve mental health outcomes.
Amarasena et al. (2023) discuss manipulation of the gut microbiome using probiotics and nutraceuticals, citing preliminary clinical evidence for symptom improvement in anxiety and depression, though they note variability in study quality.
Caveats and uncertainty
Most human studies are observational or small-scale interventional trials with heterogeneous methodologies.
Causality between microbiome alterations and psychiatric symptoms remains to be definitively established.
Individual variability in microbiome composition challenges generalized treatment approaches.
Optimal strains, doses, and treatment durations for probiotics or nutraceuticals are not standardized.
Long-term safety and efficacy data are lacking.
How this may change practice
Clinicians should consider the gut-brain axis as a potential contributor to anxiety and depression, particularly in patients with gastrointestinal comorbidities.
Dietary counseling emphasizing microbiome-friendly foods may be a low-risk adjunctive strategy.
Probiotic or nutraceutical supplementation could be considered on a case-by-case basis, with attention to emerging evidence and patient preferences.
Collaboration with nutritionists and gastroenterologists may enhance integrated care.
Future guidelines may incorporate microbiome-targeted therapies pending confirmatory trials.